Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ascendant-221 is a humanized anti-IgE IgG1 monoclonal antibody that has a dual mechanism of action; it neutralizes free IgE with picomolar potency and…
Cue Biopharma announced today that it has entered into an exclusive license agreement with Ascendant Health Sciences Ltd. to develop, manufacture and…
Cue Biopharma's Q1 2026 results: collaboration revenue $5.7M (vs $0.4M YoY), net loss $5.2M (vs $12.3M), cash $16.4M at 3/31/2026; subsequent to quarter-end…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Cue Biopharma (CUE) entered an exclusive global (ex-Greater China) license from Ascendant Health Sciences for Phase 2-stage anti-IgE antibody Ascendant-221 for $15M upfront plus up to $676.5M in development/regulatory/commercial milestones plus tiered royalties. Cue plans to initiate a global Phase 2b food-allergy trial after the China CSU readout in 2H 2026. UPDATE (Q1 2026 reporting): Cue has redesignated the in-licensed asset CUE-221 (formerly Ascendant-221); the China CSU Phase 2 readout remains expected in 2H 2026 and the global food-allergy Phase 2b remains gated on that data. Cue reported $16.4M cash at 3/31/2026 plus a subsequent $30M private placement and a $7.5M milestone receipt, funding milestones into 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cue Biopharma, Inc. / Ascendant Health Sciences Ltd. (Ascendant-221) (this deal) | 2026 | $692M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · Immunology deals